Insights

IP Expansion Compugen has recently expanded its intellectual property portfolio with a new U.S. patent covering the triple combination use of its potential anti-cancer antibodies. This broad method of use patent protection presents a significant sales opportunity for licensing deals or collaborations with other pharmaceutical companies.

Clinical Data Success Clinical data presented by Compugen at SITC 2024 demonstrated the effectiveness of its anti-cancer antibodies, showing anti-tumor activity with durable responses and good tolerability. This success in clinical trials opens up potential sales opportunities for partnerships with healthcare providers or distribution agreements for the upcoming Phase 1 trials.

Financial Stability Despite a slight earnings miss, Compugen maintains a solid financial position with a reported revenue range of $10-50 million and recent funding of $20 million. This financial stability provides a strong foundation for negotiating favorable sales terms, such as volume discounts or extended payment schedules, with potential clients or partners.

Market Visibility Compugen continues to actively participate in industry conferences and events, such as the upcoming Stifel 2024 Healthcare Conference. This consistent market presence enhances brand visibility and creates networking opportunities for potential sales leads or collaborations with key stakeholders in the biotechnology and pharmaceutical sectors.

Innovative Tech Stack With a tech stack that includes Snowplow, Redux, Java, and more, Compugen leverages cutting-edge technologies in its therapeutic discovery and development processes. Utilizing innovative tech solutions can be leveraged as a unique selling point to attract tech-savvy clients or partners seeking advanced biotechnology solutions.

Compugen Tech Stack

Compugen uses 8 technology products and services including Snowplow, Redux, Office 365, and more. Explore Compugen's tech stack below.

  • Snowplow
    Analytics
  • Redux
    Javascript Frameworks
  • Office 365
    Office Suites
  • UNIX
    Operating Systems
  • Elementor
    Page Builders
  • Java
    Programming Languages
  • Django
    Web Frameworks
  • Nginx
    Web Servers

Media & News

Compugen's Email Address Formats

Compugen uses at least 1 format(s):
Compugen Email FormatsExamplePercentage
First.Last@cgen.comJohn.Doe@cgen.com
44%
FLast@cgen.comJDoe@cgen.com
33%
FirstLast@cgen.comJohnDoe@cgen.com
15%
FirstL@cgen.comJohnD@cgen.com
8%

Frequently Asked Questions

Where is Compugen's headquarters located?

Minus sign iconPlus sign icon
Compugen's main headquarters is located at Tel Aviv, Israel IL. The company has employees across 4 continents, including AsiaNorth AmericaEurope.

What is Compugen's phone number?

Minus sign iconPlus sign icon
You can contact Compugen's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Compugen's stock symbol?

Minus sign iconPlus sign icon
Compugen is a publicly traded company; the company's stock symbol is CGEN.

What is Compugen's official website and social media links?

Minus sign iconPlus sign icon
Compugen's official website is cgen.com and has social profiles on LinkedIn.

How much revenue does Compugen generate?

Minus sign iconPlus sign icon
As of November 2024, Compugen's annual revenue reached $35M.

What is Compugen's SIC code NAICS code?

Minus sign iconPlus sign icon
Compugen's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Compugen have currently?

Minus sign iconPlus sign icon
As of November 2024, Compugen has approximately 108 employees across 4 continents, including AsiaNorth AmericaEurope. Key team members include Chief Executive Officer: E. C.Chief Executive Officer: C. L.Chief Executive Officer: R. B.. Explore Compugen's employee directory with LeadIQ.

What industry does Compugen belong to?

Minus sign iconPlus sign icon
Compugen operates in the Biotechnology Research industry.

What technology does Compugen use?

Minus sign iconPlus sign icon
Compugen's tech stack includes SnowplowReduxOffice 365UNIXElementorJavaDjangoNginx.

What is Compugen's email format?

Minus sign iconPlus sign icon
Compugen's email format typically follows the pattern of . Find more Compugen email formats with LeadIQ.

How much funding has Compugen raised to date?

Minus sign iconPlus sign icon
As of November 2024, Compugen has raised $20M in funding. The last funding round occurred on Nov 11, 2021 for $20M.
Compugen

Compugen

Biotechnology ResearchIsrael, Israel51-200 Employees

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Section iconCompany Overview

Headquarters
Tel Aviv, Israel IL
Phone number
Website
cgen.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
CGEN
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $20M

    Compugen has raised a total of $20M of funding over 5 rounds. Their latest funding round was raised on Nov 11, 2021 in the amount of $20M.

  • $10M$50M

    Compugen's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $20M

    Compugen has raised a total of $20M of funding over 5 rounds. Their latest funding round was raised on Nov 11, 2021 in the amount of $20M.

  • $10M$50M

    Compugen's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.